Atossa Therapeutics (NASDAQ:ATOS) Stock Falls Sharply From The Recent Peak
Those investors who are currently looking into the possibility of investing in biopharmaceutical stocks could do well to take a look at the Atossa Therapeutics (NASDAQ:ATOS) stock.
It has emerged as one of the major gainers so far this year despite having performed poorly in recent week. Over the course of the past month, the stock declined by 49% but at the same time, it is necessary for investors to remember that despite that fall the Atossa stock is still up by a staggering 340% in 2021 so far.
In recent days there has been no new about the company but earlier on in the month the company announced that it was awarded the much needed regulatory approval for starting a clinical study into AT H201 in Australia. The approval was awarded by the Human Research Ethics Committee.
The product is meant for providing critically ill COVID 19 patients with an inhalation therapy option. However, it has also been pointed out that the product could also be used by patients with other kinds of pulmonary infections. While the decline in the Atossa stock over the past month has been considerable, it might still prove to be an opportunity for new investors.
Market Reaction:
On Friday, ATOS stock gained 1.70% at $4.18 with more than 21.16 million shares, compared to its average volume of 21.69 million shares. The stock has moved within a range of $3.7800 – 4.5700 after opening the trade at $4.04. Over the past 52-week, the stock has been trading within a range of $0.8100 – 9.8000.
